PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16330141-0	2006	Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation.	Azoles	29-35	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	20-25	
16330141-4	2006	Inhibition of CYP19 (aromatase) is the working principle for tumor therapy, but is an unwanted side effect of azoles used as fungicides or antifungal drugs.	Azoles	110-116	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	14-19	
16330141-5	2006	The inhibition of recombinant human CYP19 by 21 azoles in use for the three different purposes was investigated using the natural substrate testosterone.	Azoles	48-54	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	36-41	
31330226-2	2019	The aim of this study was to mechanistically investigate the endocrine disrupting potential of four commonly used azole antifungal drugs; clotrimazole, miconazole, ketoconazole and fluconazole in vitro using the H295R cell assay and two recombinant, CYP17A1 and CYP19A1 (aromatase), assays.	Azoles	114-119	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	262-269	
15380230-2	2004	Azole derivatives such as letrozole or anastrozole have been developed for aromatase inhibition and are used for the treatment of breast tumors.	Azoles	0-5	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	75-84	
15554355-0	2004	Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans.	Azoles	83-89	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	62-67	
15554355-2	2004	Antifungal activity is based on inhibition of fungal CYP51 (lanosterol 14alpha-demethylase), and estrogen biosynthesis reduction is due to azole inhibition of CYP19 (aromatase).	Azoles	139-144	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	159-164	
15554355-4	2004	A fluorimetric assay based on human recombinant CYP19 enzyme with dibenzylfluorescein as a substrate was used to compare the inhibitory potency of 22 azole compounds.	Azoles	150-155	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	48-53	
35176449-0	2022	Exploration of structural requirements for azole chemicals towards human aromatase CYP19A1 activity: Classification modeling, structure-activity relationships and read-across study.	Azoles	43-48	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	83-90	
35176449-4	2022	A toxicological evaluation of commonly used azole-based drugs and agrochemicals with respect to CYP19A1is currently requested by the European Union- Registration, Evaluation, Authorization and Restriction of Chemicals (EU-REACH) regulations due to their potential as endocrine disruptors.	Azoles	44-49	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	96-103	
32435378-0	2020	Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors.	Azoles	78-83	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	48-57	
32435378-5	2020	In this context, here we designed, synthesized, and performed in vitro inhibitory tests on the aromatase enzyme and distinct ER+/ER- BC cell line types of novel azole bridged xanthones.	Azoles	161-166	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	95-104	
32046297-5	2020	This theoretical study investigated the active agonist and antagonist properties of "chemical classes of azoles" to determine the relationships of azole interaction with CYP19A1, using stereochemical and electronic properties of the molecules through classification and multilinear regression (MLR) modeling.	Azoles	105-111	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	170-177	
32046297-5	2020	This theoretical study investigated the active agonist and antagonist properties of "chemical classes of azoles" to determine the relationships of azole interaction with CYP19A1, using stereochemical and electronic properties of the molecules through classification and multilinear regression (MLR) modeling.	Azoles	105-110	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	170-177	
32046297-10	2020	This study proposes that the electron penetration of azoles toward heme group decides the binding behavior and stereochemistry requirement for antagonist activity against CYP19A1 enzyme.	Azoles	53-59	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	171-178	
24274332-6	2014	Inhibition of other CYPs, such as aromatase (CYP19), can lead to numerous toxicological effects, which are also evident from high dose human exposures to therapeutic azoles.	Azoles	166-172	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	45-50	
19500885-2	2009	Aromatase inhibition is usually achieved with steroids structurally related to the substrate of catalysis or, alternatively, with azole non-steroid compounds.	Azoles	130-135	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	0-9